Don't miss out on news and valuable information for Alphas about PROLASTIN-C LIQUID.

Wherever you are in your alpha-1 journey, you’re not alone. Whether you’re considering PROLASTIN-C LIQUID or want to make the most of your current experience with PROLASTIN-C LIQUID, we’re here for you. Sign up to join the community and receive the latest news about alpha-1, PROLASTIN-C LIQUID, and the PROLASTIN DIRECT® program.

D3 Prolastin Liquid Form

All fields are required unless otherwise stated

I was recently diagnosed with alpha-1
I have been diagnosed with alpha-1 for a while
I am currently prescribed/taking PROLASTIN-C LIQUID
I have a loved one with alpha-1
Check this box to confirm that you agree to give permission to use your personal information to receive product, disease-state, and other helpful information from Grifols and service providers and parties acting on its behalf. You may revoke your permission at any time. To learn how Grifols will use and protect your personal information, please review our Privacy Policy and Terms of Use.

Important Safety Information

PROLASTIN®-C LIQUID is an alpha1-proteinase inhibitor (human) (alpha1-PI) indicated for chronic augmentation and maintenance therapy in adults with clinical evidence of emphysema due to severe hereditary deficiency of alpha1-PI (Alpha1-antitrypsin deficiency).

 

Limitations of Use

  • The effect of augmentation therapy with any alpha1-PI, including PROLASTIN-C LIQUID, on pulmonary exacerbations and on the progression of emphysema in alpha1-PI deficiency has not been conclusively demonstrated in randomized, controlled clinical trials
  • Clinical data demonstrating the long-term effects of chronic augmentation or maintenance therapy with PROLASTIN-C LIQUID are not available
  • PROLASTIN-C LIQUID is not indicated as therapy for lung disease in patients in whom severe alpha1-PI deficiency has not been established

PROLASTIN-C LIQUID is contraindicated in immunoglobulin A (IgA)-deficient patients with antibodies against IgA or patients with a history of anaphylaxis or other severe systemic reaction to alpha1-PI products.


Hypersensitivity reactions, including anaphylaxis, may occur. Monitor vital signs and observe the patient carefully throughout the infusion. If hypersensitivity symptoms occur, promptly stop PROLASTIN-C LIQUID infusion and begin appropriate therapy.


Because PROLASTIN-C LIQUID is made from human plasma, it may carry a risk of transmitting infectious agents, eg, viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. This also applies to unknown or emerging viruses and other pathogens.


The most common adverse reactions during PROLASTIN-C LIQUID clinical trials in >5% of subjects were diarrhea and fatigue, each of which occurred in 2 subjects (6%).

 

Please see full Prescribing Information for PROLASTIN-C LIQUID.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit  http://www.fda.gov/medwatch, or call 1-800-FDA-1088.